Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Belumosudil (Rezurock) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
• A study from a Phase 2 randomized multicenter registration study evaluated the efficacy and safety profile of belumosudil in treating cGVHD.
• The patient population included subjects who had received between 2 to 5 prior lines of systemic therapy, indicating resistance or inadequate response to existing treatments. High response rates were observed across all subgroups suggesting broad effectiveness within this demographic.
• Efficacy results showed high overall response rates: 74% for the daily dose regimen and 77% for twice-daily dosing. This indicates a strong therapeutic effect on treated patients. Additionally, symptom reduction was reported in over half the subjects, highlighting significant quality-of-life improvement.
• Safety evaluation revealed that adverse events were consistent with expectations for this patient group; no additional risks beyond those associated with other cGVHD treatments seem apparent from using belumosudil. Only twelve percent discontinued due to possible drug-related adverse events, implying relatively favorable tolerability given the challenging treatment landscape of cGVHD.
• Based on its demonstrated high efficacy across various patient subgroups along with a manageable safety profile, belumosudil could offer an effective alternative especially when previous therapies have failed.